Surrozen (SRZN) Stock Forecast & Price Target

Surrozen is making significant progress in their development of drug candidates targeting the Wnt pathway for tissue repair in a variety of organs and tissues. The company has a strong financial standing with a substantial net gain of $50.2M in 2Q26 and $106.9M in cash as of March 31, 2026. With the anticipated IND submission for SZN-8141 in 2H26 and continued progress in their other preclinical candidates, the company has the potential to address the unmet need for durable therapies in retinal vascular diseases, positioning them for success in the developmental-stage biopharmaceutical market.

Surrozen is a clinical-stage biotechnology company that has a negative outlook from a financial analyst due to concerns about the potential success and differentiation of its lead product candidate, SZN-8141, in the competitive field of Wnt therapies. Additionally, the company's high R&D and G&A expenses, coupled with a net loss of $242.0M in 2025, may pose financial risks for investors. Despite the positive update on the company's intellectual property position and partnership with Boehringer Ingelheim, the lack of concrete evidence on the translation of preclinical signals to the clinic leaves some uncertainty about the potential of Surrozen's candidates in the near-term.